|

RET Inhibitor Clinical Trials

2 actively recruiting trials

Also known as: Pralsetinib, Selpercatinib

Top Sponsors

  • Fujian Medical University1
  • Fudan University1

Indications

  • Thyroid Cancer2
  • Cancer2
  • Thyroid Neoplasms1

Other2 trials

RET Inhibitor for Neoadjuvant Therapy in Locally Advanced RET-altered Thyroid Cancer
Response to Neoadjuvant Treatment in Locally Advanced Thyroid Cancer

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.